HRP20050563A2 - Methods for predicting therapeutic response to agents acting on the growth hormone receptor - Google Patents

Methods for predicting therapeutic response to agents acting on the growth hormone receptor Download PDF

Info

Publication number
HRP20050563A2
HRP20050563A2 HR20050563A HRP20050563A HRP20050563A2 HR P20050563 A2 HRP20050563 A2 HR P20050563A2 HR 20050563 A HR20050563 A HR 20050563A HR P20050563 A HRP20050563 A HR P20050563A HR P20050563 A2 HRP20050563 A2 HR P20050563A2
Authority
HR
Croatia
Prior art keywords
subject
agent
allele
ghr
ghrd3
Prior art date
Application number
HR20050563A
Other languages
English (en)
Croatian (hr)
Inventor
Bougneres Pierre
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Publication of HRP20050563A2 publication Critical patent/HRP20050563A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
HR20050563A 2002-12-19 2005-06-16 Methods for predicting therapeutic response to agents acting on the growth hormone receptor HRP20050563A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43486102P 2002-12-19 2002-12-19
PCT/IB2003/005111 WO2004056864A1 (en) 2002-12-19 2003-11-10 Methods for predicting therapeutic response to agents acting on the growth hormone receptor

Publications (1)

Publication Number Publication Date
HRP20050563A2 true HRP20050563A2 (en) 2005-12-31

Family

ID=23725994

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050563A HRP20050563A2 (en) 2002-12-19 2005-06-16 Methods for predicting therapeutic response to agents acting on the growth hormone receptor

Country Status (12)

Country Link
US (1) US20040180358A1 (zh)
EP (1) EP1572738A1 (zh)
JP (1) JP2006525785A (zh)
KR (1) KR20050085855A (zh)
CN (1) CN1747968A (zh)
AU (1) AU2003278503A1 (zh)
CA (1) CA2510045A1 (zh)
HR (1) HRP20050563A2 (zh)
NO (1) NO20053490L (zh)
RU (1) RU2005122665A (zh)
SE (1) SE0300959D0 (zh)
WO (1) WO2004056864A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0512709A (pt) * 2004-07-08 2008-04-01 Pharmacia & Upjohn Co Llc métodos para prognóstico da resposta terapêutica a agentes atuando no receptor do hormÈnio do crescimento
GB0600122D0 (en) * 2006-01-05 2006-02-15 Univ Cardiff Mutation in the growth hormone receptor
US20080299659A1 (en) * 2007-03-02 2008-12-04 Nastech Pharmaceutical Company Inc. Nucleic acid compounds for inhibiting apob gene expression and uses thereof
EP2440241B1 (en) * 2009-06-08 2017-08-09 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
IN2012DN02485A (zh) * 2009-09-03 2015-08-28 Hoffmann La Roche
US20150133383A1 (en) * 2012-05-11 2015-05-14 Prorec Bio Ab Method for diagnosis and treatment of prolactin associated disorders
CN103014007A (zh) * 2012-11-22 2013-04-03 新疆旺源驼奶实业有限公司 双峰驼α-乳白蛋白基因、重组蛋白及其克隆方法
CN103014005A (zh) * 2012-11-22 2013-04-03 新疆旺源驼奶实业有限公司 双峰驼a-fabp蛋白基因、重组蛋白及其克隆方法
CN103014008A (zh) * 2012-11-22 2013-04-03 新疆旺源驼奶实业有限公司 双峰驼ghr蛋白基因、重组蛋白及其克隆方法
CN112322657B (zh) * 2020-11-12 2023-04-25 浙江新码生物医药有限公司 一种人生长激素的体外活性检测方法
EP4355760A1 (en) 2021-06-18 2024-04-24 PeptiDream Inc. Ghr-binding pending peptide and composition comprising same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210017A (en) * 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5824642A (en) * 1994-04-07 1998-10-20 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
AU723494B2 (en) * 1996-02-13 2000-08-31 Jcr Pharmaceuticals Co., Ltd. Mutant human growth hormones and their uses
US6080911A (en) * 1997-04-15 2000-06-27 Ohio University Mice models of growth hormone insensitivity

Also Published As

Publication number Publication date
US20040180358A1 (en) 2004-09-16
SE0300959D0 (sv) 2003-04-02
CA2510045A1 (en) 2004-07-08
NO20053490D0 (no) 2005-07-18
JP2006525785A (ja) 2006-11-16
KR20050085855A (ko) 2005-08-29
AU2003278503A1 (en) 2004-07-14
CN1747968A (zh) 2006-03-15
WO2004056864A1 (en) 2004-07-08
EP1572738A1 (en) 2005-09-14
NO20053490L (no) 2005-09-16
RU2005122665A (ru) 2006-01-20

Similar Documents

Publication Publication Date Title
HRP20050563A2 (en) Methods for predicting therapeutic response to agents acting on the growth hormone receptor
CA2588765C (en) Treatment of neurodegenerative disease with angiogenin and its mutants
US20090317816A1 (en) Methods for identifying risk of breast cancer and treatments thereof
US20050064440A1 (en) Methods for identifying risk of melanoma and treatments thereof
AU2003248794B2 (en) Therapeutic methods for reducing fat deposition and treating associated conditions
US20050277118A1 (en) Methods for identifying subjects at risk of melanoma and treatments thereof
US20080199480A1 (en) Methods for Identifying Risk of Type II Diabetes and Treatments Thereof
US20040018533A1 (en) Diagnosing predisposition to fat deposition and therapeutic methods for reducing fat deposition and treatment of associated conditions
AU2790701A (en) Methods for diagnosing and treating heart disease
WO2006022619A2 (en) Methods for identifying risk of type ii diabetes and treatments thereof
US20080070248A1 (en) Methods for Predicting Therapeutic Response to Agents Acting on the Growth Hormone Receptor
WO2006001981A2 (en) Methods for treating disease by modulating an osmotic stress pathway
WO2006022633A1 (en) Methods for identifying a risk of type ii diabetes and treatments thereof
JP2003532430A (ja) ヒトにおける成長ホルモン異形の検出方法、上記異形及びそれらの使用
US20050118606A1 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2012168399A1 (en) Methods for predicting, treating and modelling hormone resistance
US20080319176A1 (en) Glycerol as a predictor of glucose tolerance

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20071018

Year of fee payment: 5

OBST Application withdrawn